This randomized, double-blind, placebo-controlled trial assessed the efficacy of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, in mitigating cardiovascular morbidity and mortality in patients with type 2 diabetes and elevated cardiovascular risk. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.